The earnings call reflects a mixed sentiment. While the Specialty Pharma business and international expansion showed strong growth, the overall revenue decline and significant drop in CDMO sales impacted profitability. Positive R&D developments and awarded aid provide optimism, but financial challenges in the CDMO segment and decreased profitability metrics weigh heavily.

Company Guidance -

Q3 2025

In the call discussing ROVI's first half of 2025 financial results, the company reiterated its guidance for the year, expecting operating revenue to decrease by a mid-single-digit percentage compared to 2024. Despite a 4% decline in overall operating revenue to EUR 314.6 million due to the underperformance in the contract development and manufacturing organization (CDMO) segment, the Specialty Pharma business saw a 13% increase in sales, reaching EUR 237.4 million. This growth was driven by a significant rise in Okedi sales by 115% to EUR 26.9 million, and a 14% increase in enoxaparin sales to EUR 79.8 million. The gross margin improved by 3 percentage points to 62.4%, despite EBITDA decreasing by 6% to EUR 65.6 million, primarily due to higher R&D expenses. ROVI continues to focus on innovation in its Specialty Pharma area, with ongoing investments in new formulations and international expansion, particularly in the heparin division.

Specialty Pharma Business Growth

Sales of the Specialty Pharma business increased 13% to EUR 237.4 million in the first half of 2025. The Okedi monthly Risperidone ISM saw a sales increase of 115% to EUR 26.9 million, and the Heparin division's sales rose by 12% to EUR 135.2 million.

Technological Development and Innovation Center Aid

ROVI was awarded EUR 36.3 million for the LAISOLID project by the Technological Development and Innovation Center, covering expenses from January 2023 to August 2026.

International Expansion

ROVI's sales outside Spain represented 55% of operating revenue in the first half of 2025, with the enoxaparin biosimilar now present in 42 countries.

Positive R&D Developments

ROVI is advancing with the clinical trials for Letrozole SIE and quarterly Risperidone ISM, having obtained positive results in Phase I trials and preparing for Phase III trials.

Laboratorios Farmaceuticos Rovi (GB:0ILL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:0ILL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	- / -	0.86	―	―	―
Jul 24, 2025	2025 (Q2)	- / 0.42	0.86	-50.81% (-0.44)	―	―
May 08, 2025	2025 (Q1)	- / 0.35	0.289	22.49% (+0.07)	―	―
Feb 25, 2025	2024 (Q4)	- / 0.46	0.994	-54.02% (-0.54)	―	―
Nov 07, 2024	2024 (Q3)	- / 1.36	0.978	39.47% (+0.39)	―	―
Jul 31, 2024	2024 (Q2)	- / 0.86	0.36	138.89% (+0.50)	―	―
May 08, 2024	2024 (Q1)	- / 0.29	0.889	-67.49% (-0.60)	―	―
Feb 27, 2024	2023 (Q4)	- / 0.99	1.464	-32.10% (-0.47)	―	―
Nov 08, 2023	2023 (Q3)	- / 0.98	0.797	22.71% (+0.18)	―	―
Jul 26, 2023	2023 (Q2)	- / 0.36	0.51	-29.41% (-0.15)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:0ILL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	€54.39	€56.54	+3.95%
May 08, 2025	€50.50	€53.02	+4.99%
Feb 25, 2025	€54.50	€54.26	-0.44%
Nov 07, 2024	€74.28	€65.45	-11.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Laboratorios Farmaceuticos Rovi (GB:0ILL) report earnings?

Laboratorios Farmaceuticos Rovi (GB:0ILL) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Laboratorios Farmaceuticos Rovi (GB:0ILL) earnings time?

Laboratorios Farmaceuticos Rovi (GB:0ILL) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Laboratorios Farmaceuticos Rovi stock?

The P/E ratio of Laboratorios Farmaceuticos Rovi is N/A.

What is GB:0ILL EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing